The direct-to-patient service is designed to support trials and help to minimize trial length and costs, while boosting enrollment and participation rates.
A leader from the genetic solutions firm explains how genetic testing and counseling can help trial teams form more beneficial connections with patients.
An executive from the rare disease technology solutions company discusses how forcing connections with patients can boost research into such conditions.
An executive from the clinical trial technology provider will share how direct data capture can save time, avoid errors and improve the patient experience.
The annual event, moved to the virtual realm thanks to COVID-19, offers content on remote monitoring, drug development technology and other key topics.
The collaboration will leverage patients’ biological and medical data to streamline patient identification and recruitment efforts in clinical research.
A leader from the clinical data solutions firm explains how the challenges created by the pandemic have helped fuel creativity and innovation in studies.
William Gholston, with the Tampa Bay Buccaneers football team, is donating to the Moffitt Cancer Center to fund research into cancer treatment disparities.
With fewer than 3% of analyzed genomes currently coming from Africans, the companies are looking to increase access to and understanding of patient data.
Conducted by SubjectWell, the survey of patients with Type 2 diabetes reveals how ethnicity and other factors play a part in trial participation tendencies.
Conducted via a partnership between Parexel and CISCRP, the study reveals insights about the needs and concerns of pediatric patients and their families.
A leader from the clinical trial solutions firm talks about the drive toward conducting trials without sites, and why that idea might lead to problems.
The head of the CRO’s Global Center of Excellence for Decentralized Clinical Trial Strategy outlines key developments in 2020, and keys to success in 2021.
A real-world evidence generation expert discusses how clinical trial teams can make use of RWE to help improve diversity and inclusivity in their studies.
Taking place December 9, the Digital Advances in Clinical Trials webinar covers notable advances in clinical trial technology, and the future of the field.
A leader from the global CRO shares an update on their new Accellacare clinical research network, and perspective on the importance of patient centricity.
A leader from the CRO discusses how the COVID-19 pandemic has accelerated decentralized adoption, and how such trials lead to benefits for participants.
According to one New Yorker, encountering the AI-assisted TrialJectory technology helped cut through the uncertainty to provide information and solutions.
The precision medicine firm is joining with the oncology network in an effort to help improve treatment options and outcomes for cancer patients worldwide.
An expert from the global pharmaceutical firm shares how working with other organizations and putting patients at the center can benefit clinical research.
A leader from the cancer patient matching and analysis solutions firm discusses how and other forces are pushing innovation in the oncology research space.
This year the conference brings its content, focused on the intersection of clinical research and patient care, from the real world to the virtual one.
The pharmaceutical firm’s More to uS is a UK-centered campaign that shares stories of people living (and thriving) after a multiple sclerosis diagnosis.
A veteran with more than 20 years of experience talks about the vitality of recruiting an inclusive patient population, and the perils of falling short.
A leader from home-based clinical services firm Illingworth Research Group talks about the evolution of mobile nursing and how it can keep trials going.
A leader from the clinical trial patient engagement specialist discusses how clinical trial teams can tackle tricky travel issues in the face of the pandemic.
A leader with the patient recruitment specialist talks about the need for clinical trials to balance their important work with what’s important to participants.
